

AMENDMENTS TO THE CLAIMS

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) Antisolvent solidification process for preparing a solid composition comprising at least one organic or inorganic compound, wherein a liquid medium comprising at least one dissolved organic or inorganic compound is forced through a membrane which is positioned in a membrane module into one or more antisolvents or wherein one or more antisolvents are forced through a membrane which is positioned in a membrane module into a liquid medium comprising at least one organic or inorganic compound, and whereby the process is carried out as a continuous process and the membrane has up to 3 µm pores and the shape of the membrane is selected from tubes, fibres, and spiral wounds, yielding a composition comprising solid particles comprising said organic and/or inorganic compound(s).
2. (Original) A process according to claim 1 wherein the solidification is a crystallisation, the prepared solid particles are crystalline particles, the organic or inorganic compound is a crystallisable compound, and, optionally, said crystalline particles are recovered from the process.
3. (Previously Presented) A process according to claim 1 wherein the liquid medium is separated from the one or more antisolvents by means of nanofiltration and wherein, optionally, the liquid medium and/or the antisolvent(s) is/are recycled.
4. (Previously Presented) A process according to claim 1 wherein an emulsion is formed before said composition comprising solid particles is obtained.
5. (Previously Presented) A process according to claim 1 wherein a nonsolvent is present in the liquid medium and/or in the one or more antisolvents.
6. (Previously Presented) A process according to claim 1 wherein the organic or inorganic compound is selected from the group consisting of transition metal compounds, transition metal salts, alkali salts, alkali earth salts, fatty acids, proteins, saccharides, aminoacids, and pigments.

7. (Previously Presented) A process according to claim 1 wherein the solid particles essentially consist of particles of only one inorganic or organic compound.
8. (Previously Presented) A process according to claim 1 wherein the inorganic or organic compound is a pharmaceutical compound.
9. (Original) A process according to claim 8 wherein the pharmaceutical compound is selected from the group consisting of tibolone, progesterone, desogestrel, and 3-ketodesogestrel (etonogestrel).
10. (Previously Presented) A process according to claim 1 wherein the solid composition comprises a mixture of two or more pharmaceutical compounds.
11. (Previously Presented) A process according to claim 1 wherein a composition comprising solid particles is prepared, in which composition at least part of the particles consists of a core coated with one or more solid coatings of one or more organic or inorganic coating materials, by forcing a liquid medium comprising dissolved organic or inorganic coating material through a membrane into a suspension of particles to be coated in one or more antisolvent(s) for said coating material.
12. (Original) A process according to claim 11 wherein the prepared solid composition comprises particles having a core comprising a pharmaceutical compound coated with at least one or more coating materials which comprise a pharmaceutical compound.
13. (Withdrawn) Crystalline particles obtainable by the process of claim 1 comprising at least one pharmaceutical compound which is preferably selected from the group consisting of tibolone, progesterone, desogestrel, and 3-keto-desogestrel (etonogestrel) showing only little and preferably essentially no agglomeration and having a span of the particle size distribution immediately after the crystallisation step of below 3.
14. (Withdrawn) A pharmaceutical dosage form comprising crystalline particles according to claim 13.
15. (Withdrawn) A pharmaceutical dosage form comprising crystalline particles according to claim 13 wherein the dosage form is a tablet.
16. (Cancelled).

17. (Withdrawn) A method of using the crystalline particles according to claim 13 in the preparation of a pharmaceutical dosage form.
18. (New) A process according to claim 1 wherein in an additional step a pharmaceutical dosage form is prepared from the composition comprising solid particles comprising said organic and/or inorganic compound(s).
19. (New) A process according to claim 18 wherein the dosage form is a tablet.
20. (New) A process according to claim 18 wherein the dosage form is a product for inhalation.